Washington, D.C. 20549







Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported):

October 21, 2019



10x Genomics, Inc.

(Exact name of registrant as specified in its charter)




Delaware   001-39035   45-5614458

(State or other jurisdiction

of incorporation)



File Number)


(IRS Employer

Identification No.)

6230 Stoneridge Mall Road

Pleasanton, California 94588

(925) 401-7300

(Address, including zip code, and telephone number, including area code, of registrant’s principal executive offices)



Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:


Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)


Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)


Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))


Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e- 4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class


Trading Symbol


Name of each exchange on which registered

Class A common stock, par value $0.00001 per share    TXG    The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company  ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐




Item 7.01

Regulation FD Disclosure.

The Becton, Dickinson Action and Patent Cross License

As previously disclosed, 10x Genomics, Inc. (the “Company”) has been involved in patent litigation with Becton, Dickinson and Company (“BD”) and Cellular Research, Inc. In November 2018, BD and Cellular Research, Inc. (together, the “BD Entities”) alleged that the Company infringed certain patents. In September 2019, the Company filed counterclaims alleging that the BD Entities infringed a number of the Company’s patents. The Company recently entered into a settlement and patent cross license agreement (the “Agreement”) with the BD Entities.

The Agreement resolved all currently outstanding patent litigation between the parties (the “Litigation”), which was dismissed with prejudice on October 21, 2019. Under the terms of the Agreement, the BD Entities granted the Company and its affiliates, and the Company granted BD and its affiliates, a worldwide, royalty-free, non-exclusive, fully paid-up license to certain patents and patent applications relating to molecular barcoding and single cell analysis, including to all the patents asserted in the Litigation. The Company will make an aggregate payment of $25 million to BD in annual amounts of $6.25 million over four years beginning in January 2020 in connection with the Agreement. As part of the Agreement, each party, on behalf of itself and its affiliates, has also entered into a covenant not to sue in certain fields related to each company’s products. The companies have also agreed on behalf of themselves and their affiliates to refrain from challenging the patents and patent applications licensed under the Agreement.

The information furnished pursuant to Item 7.01 in this Current Report on Form 8-K shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any other filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.


Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


10x Genomics, Inc.

/s/ Eric S. Whitaker

Name:   Eric S. Whitaker
Title:   General Counsel

Date: October 21, 2019